Jane Street Group LLC Buys 30,481 Shares of Nektar Therapeutics (NASDAQ:NKTR)

Jane Street Group LLC grew its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 50.0% in the 3rd quarter, HoldingsChannel reports. The firm owned 91,470 shares of the biopharmaceutical company’s stock after acquiring an additional 30,481 shares during the quarter. Jane Street Group LLC’s holdings in Nektar Therapeutics were worth $119,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Victory Capital Management Inc. bought a new position in Nektar Therapeutics during the 2nd quarter worth approximately $29,000. Valence8 US LP purchased a new stake in Nektar Therapeutics in the third quarter worth about $34,000. Intech Investment Management LLC bought a new stake in shares of Nektar Therapeutics during the third quarter valued at approximately $41,000. Erste Asset Management GmbH purchased a new stake in shares of Nektar Therapeutics in the 3rd quarter worth about $61,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Nektar Therapeutics during the 3rd quarter valued at about $86,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Insider Transactions at Nektar Therapeutics

In other Nektar Therapeutics news, CEO Howard W. Robin sold 46,995 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the sale, the chief executive officer now directly owns 1,195,710 shares of the company’s stock, valued at approximately $1,207,667.10. This represents a 3.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Andrew Wilson sold 33,402 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the completion of the sale, the insider now owns 351,892 shares in the company, valued at $316,702.80. The trade was a 8.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 155,575 shares of company stock valued at $149,878 in the last 90 days. 3.71% of the stock is currently owned by insiders.

Nektar Therapeutics Trading Down 6.4 %

Shares of NKTR opened at $0.90 on Wednesday. Nektar Therapeutics has a 12-month low of $0.48 and a 12-month high of $1.93. The company’s 50 day simple moving average is $1.07 and its 200-day simple moving average is $1.21. The firm has a market cap of $166.01 million, a PE ratio of -1.07 and a beta of 0.59.

Analyst Ratings Changes

Several analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and set a $6.50 price target on shares of Nektar Therapeutics in a report on Monday. B. Riley assumed coverage on Nektar Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price target on the stock. Piper Sandler assumed coverage on Nektar Therapeutics in a research note on Monday, November 4th. They set an “overweight” rating and a $7.00 target price on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $4.00 price objective on shares of Nektar Therapeutics in a research note on Monday, September 30th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $4.08.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.